医药行业支付与α受体阻滞剂及膀胱过度活动症药物处方相关
本研究将Open Payments Program中医药行业对处方医生的支付数据与Medicare Part D处方数据关联,采用二项逻辑回归分析接受行业支付与开具市场推广药物(西洛多辛、非索罗定、索利那新、米拉贝隆)之间的关联。结果显示,接受行业支付与开具上述所有药物的 odds 均升高,且支付总金额和支付次数均独立相关并呈剂量反应效应。
要点
- 接受行业支付与开具西洛多辛(OR 34.1)、非索罗定(OR 5.9)、索利那新(OR 2.7)、米拉贝隆(OR 6.8)的 odds 升高相关(均 P < .001)。
- 支付总金额增加和支付频率增加均独立与开具推广药物的 odds 升高相关,呈剂量反应效应。
- 提示医药行业财务关系可能影响泌尿外科相关药物处方行为。
核心结论
- 接受医药行业支付与开具市场推广的α受体阻滞剂和膀胱过度活动症药物之间存在一致的关联。
- 支付总金额和交易次数均与开具这些药物相关。
研究设计与样本
- 将Open Payments Program行业支付数据库与Medicare Part D处方数据关联。
- 采用二项逻辑回归分析接受行业支付与开具西洛多辛、非索罗定、索利那新、米拉贝隆的关联。
- 同时评估支付总金额和支付次数增加对开具推广药物的影响。
主要发现
- 接受行业支付与开具西洛多辛的 odds 升高相关(OR 34.1,P < .001)。
- 接受行业支付与开具非索罗定的 odds 升高相关(OR 5.9,P < .001)。
- 接受行业支付与开具索利那新的 odds 升高相关(OR 2.7,P < .001)。
- 接受行业支付与开具米拉贝隆的 odds 升高相关(OR 6.8,P < .001)。
- 支付总金额增加和支付频率增加均独立与开具推广药物的 odds 升高相关,呈剂量反应效应。
关键数值与推荐
- 西洛多辛:OR 34.1(P < .001)。
- 非索罗定:OR 5.9(P < .001)。
- 索利那新:OR 2.7(P < .001)。
- 米拉贝隆:OR 6.8(P < .001)。
临床怎么用
- 泌尿外科医生应意识到医药行业支付可能与处方推广药物的倾向相关。
- 在开具α受体阻滞剂和膀胱过度活动症药物时,可审视自身财务关系对处方选择的影响。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To determine the impact of physicians' financial relationships with the pharmaceutical industry on prescribing marketed alpha-blockers and overactive bladder (OAB) medications. We also aim to examine if the number or total value of transactions is influential. MATERIALS AND METHODS: We linked the Open Payments Program database of industry payments to prescribers with Medicare Part D prescription data. We used binomial logistic regression to identify the association between receipt of industry payment and prescribing of marketed alpha-blockers (silodosin) and OAB medications (fesoterodine, solifenacin, and mirabegron). We also evaluated the impact of increasing total value and number of payments on prescribing of marketed drugs. RESULTS: The receipt of industry payment was associated with increased odds of prescribing the marketed drug for all included drugs: silodosin (odds ratio [OR] 34.1), fesoterodine (OR 5.9), solifenacin (OR 2.7), and mirabegron (OR 6.8) (all P <.001). We also found that increasing value of total payment and increasing frequency of payments were both independently associated with increased odds of prescribing with a dose-response effect. CONCLUSION: There is a consistent association between receipt of industry payment and prescribing marketed alpha-blockers and OAB medications. Both the total value and number of transactions were associated with prescribing.
引用
- Modi PK, Wang Y, Kirk PS, et al. The Receipt of Industry Payments is Associated With Prescribing Promoted Alpha-blockers and Overactive Bladder Medications. Urology. 2018. PMID: 29680480. doi:10.1016/j.urology.2018.04.008
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。